Last reviewed · How we verify
Registry
Registry is a Biologic drug developed by Hospices Civils de Lyon. It is currently in Phase 2 development.
The Sentinel Registry is a study evaluating procedural outcomes and safety of a cerebral embolic protection device for patients undergoing transcatheter aortic valve replacement. It is investigating this in routine clinical practice for patients with conditions such as Aortic Valve Disease and Diffuse Large B-cell Lymphoma.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Registry |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Valve Performance of the SAPIEN 3 Ultra RESILIA Valve: A Prospective Registry With Central Echocardiography Analysis.
- STOP-HSP.Net: a Registry for Hereditary Spastic Paraplegia as an Integration Tool for Future Therapeutic Strategies
- Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure (NA)
- Optimization of Complex Percutaneous Coronary Intervention With Liberal Use of Intracoronary Imaging Versus Contemporary Practice
- Understanding Practices of Lactation and Infant Feeding Together With Women With HIV in the United States
- Using Big Data to Conduct Innovative Cardiovascular Clinical Trials (NA)
- ILUMIEN-V - AERO: All-comEr Registry of OCT (AERO)
- Product Surveillance Registry
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Registry CI brief — competitive landscape report
- Registry updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI
Frequently asked questions about Registry
What is Registry?
Who makes Registry?
What development phase is Registry in?
Related
- Manufacturer: Hospices Civils de Lyon — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing